BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 22108195)

  • 1. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
    Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
    PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
    J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IL28B and
    Domagalski K; Pawłowska M; Zaleśna A; Pilarczyk M; Rajewski P; Halota W; Tretyn A
    World J Gastroenterol; 2016 Nov; 22(41):9186-9195. PubMed ID: 27895405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.
    Holmes JA; Nguyen T; Ratnam D; Heerasing NM; Tehan JV; Bonanzinga S; Dev A; Bell S; Pianko S; Chen R; Visvanathan K; Hammond R; Iser D; Rusli F; Sievert W; Desmond PV; Bowden DS; Thompson AJ
    J Gastroenterol Hepatol; 2013 May; 28(5):861-6. PubMed ID: 23301835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
    Wang H; Wu H; Bao S; Xiang X; Zhao G; Liu K; Li F; Xu Y; An B; Zhou H; Lu J; Xie Q
    Infect Genet Evol; 2015 Apr; 31():161-8. PubMed ID: 25640825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.
    Wu H; Zhao G; Qian F; Liu K; Xie J; Zhou H; Xu J; Xu Y; Han Y; Xie Q; Wang H
    Liver Int; 2015 Feb; 35(2):473-81. PubMed ID: 24517415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
    J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
    Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
    Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
    Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
    Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype F of hepatitis B: response to interferon.
    Venegas M; Poniachik J; Fuster F; Hurtado C; Villanueva RA; Brahm J
    Antivir Ther; 2015; 20(4):453-6. PubMed ID: 25321866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
    Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P
    Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.